Citation

Mondello S, Muller U, Jeromin A, Streeter J, Hayes RL, Wang KK. Expert Rev. Mol. Diagn. 2011; 11(1): 65-78.

Affiliation

Banyan Biomarkers, Inc., 12085 Research Drive, Alachua, FL 32615, USA.

Copyright

(Copyright © 2011, Future Drugs)

DOI

10.1586/erm.10.104

PMID

21171922

PMCID

PMC3063529

Abstract

Traumatic brain injury is a major health and socioeconomic problem that affects all societies. However, traditional approaches to the classification of clinical severity are the subject of debate and are being supplemented with structural and functional neuroimaging, as the need for biomarkers that reflect elements of the pathogenetic process is widely recognized. Basic science research and developments in the field of proteomics have greatly advanced our knowledge of the mechanisms involved in damage and have led to the discovery and rapid detection of new biomarkers that were not available previously. However, translating this research for patients' benefits remains a challenge. In this article, we summarize new developments, current knowledge and controversies, focusing on the potential role of these biomarkers as diagnostic, prognostic and monitoring tools of brain-injured patients.

Language: en